- Home
- NMS vs GUTS Comparison
NMS vs GUTS Comparison
Compare NMS & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- GUTS
- Stock Information
- Founded
- NMS 1993
- GUTS 2010
- Country
- NMS United States
- GUTS United States
- Employees
- NMS N/A
- GUTS N/A
- Industry
- NMS Finance Companies
- GUTS
- Sector
- NMS Finance
- GUTS
- Exchange
- NMS Nasdaq
- GUTS NYSE
- Market Cap
- NMS 71.8M
- GUTS 75.0M
- IPO Year
- NMS N/A
- GUTS 2024
- Fundamental
- Price
- NMS $12.30
- GUTS $1.21
- Analyst Decision
- NMS
- GUTS Buy
- Analyst Count
- NMS 0
- GUTS 1
- Target Price
- NMS N/A
- GUTS $10.00
- AVG Volume (30 Days)
- NMS 12.0K
- GUTS 216.7K
- Earning Date
- NMS 01-01-0001
- GUTS 03-03-2025
- Dividend Yield
- NMS 4.11%
- GUTS N/A
- EPS Growth
- NMS N/A
- GUTS N/A
- EPS
- NMS N/A
- GUTS N/A
- Revenue
- NMS N/A
- GUTS $93,000.00
- Revenue This Year
- NMS N/A
- GUTS N/A
- Revenue Next Year
- NMS N/A
- GUTS N/A
- P/E Ratio
- NMS N/A
- GUTS N/A
- Revenue Growth
- NMS N/A
- GUTS N/A
- 52 Week Low
- NMS $9.21
- GUTS $1.16
- 52 Week High
- NMS $12.18
- GUTS $8.37
- Technical
- Relative Strength Index (RSI)
- NMS 37.62
- GUTS 32.27
- Support Level
- NMS $12.35
- GUTS $1.27
- Resistance Level
- NMS $12.40
- GUTS $1.46
- Average True Range (ATR)
- NMS 0.07
- GUTS 0.14
- MACD
- NMS -0.01
- GUTS -0.01
- Stochastic Oscillator
- NMS 0.00
- GUTS 8.84
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.